Cargando…

The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial

BACKGROUND AND AIMS: Asthma exacerbation is defined as an acute attack of shortness of breath with more than 25% decrease in morning peak flow compared to the baseline on 2 consecutive days, which requires immediate standard therapy. The majority of asthmatic patients are considered to be steroid-se...

Descripción completa

Detalles Bibliográficos
Autores principales: Farshadfar, Kimia, Sohooli, Maryam, Shekouhi, Ramin, Taherinya, Ali, Qorbani, Mostafa, Rezaei-kojani, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630847/
https://www.ncbi.nlm.nih.gov/pubmed/34847965
http://dx.doi.org/10.1186/s40733-021-00081-1
_version_ 1784607441591205888
author Farshadfar, Kimia
Sohooli, Maryam
Shekouhi, Ramin
Taherinya, Ali
Qorbani, Mostafa
Rezaei-kojani, Mehdi
author_facet Farshadfar, Kimia
Sohooli, Maryam
Shekouhi, Ramin
Taherinya, Ali
Qorbani, Mostafa
Rezaei-kojani, Mehdi
author_sort Farshadfar, Kimia
collection PubMed
description BACKGROUND AND AIMS: Asthma exacerbation is defined as an acute attack of shortness of breath with more than 25% decrease in morning peak flow compared to the baseline on 2 consecutive days, which requires immediate standard therapy. The majority of asthmatic patients are considered to be steroid-sensitive; however, corticosteroid-resistant asthma is a subset of asthma with poor response to corticosteroids and is responsible for frequent hospital admissions. In this study we aimed to compare the effects of two enhancing strategies, the nebulized ketamine and IV magnesium sulfate, in treatment of severe steroid resistant asthma. MATERIALS AND METHODS: This double-blind randomized clinical trial was conducted on patients who presented to a referral clinic in Alborz, Iran. Using random allocation, patients were divided into two groups. The first group was treated with nebulized ketamine and the second group was treated with intravenous magnesium sulfate. Peak expiratory flow rates were assessed before the intervention, 30 and 60 min after the intervention and compared with the aid of SPSS software. RESULTS: The Peak expiratory flow rates before the intervention, 30 min and 60 min after the intervention was statistically significantly different in both ketamine and magnesium sulfate groups. Peak expiratory flow rates change between 0 and 60 min were 29.4 and 15.2% in the ketamine and magnesium sulfate group respectively. Although the ketamine group showed much higher increase in mean PEFR compared to the MgSO(4) groups, there was no statistically significant difference across both groups. CONCLUSION: Our study concluded that combined with standard therapy, both ketamine and IV magnesium sulfate are effective agents in the improvement of PEFR in patients with acute severe asthma that failed to respond to traditional therapies. However, there were no statistically significant difference between the two groups.
format Online
Article
Text
id pubmed-8630847
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86308472021-12-01 The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial Farshadfar, Kimia Sohooli, Maryam Shekouhi, Ramin Taherinya, Ali Qorbani, Mostafa Rezaei-kojani, Mehdi Asthma Res Pract Research BACKGROUND AND AIMS: Asthma exacerbation is defined as an acute attack of shortness of breath with more than 25% decrease in morning peak flow compared to the baseline on 2 consecutive days, which requires immediate standard therapy. The majority of asthmatic patients are considered to be steroid-sensitive; however, corticosteroid-resistant asthma is a subset of asthma with poor response to corticosteroids and is responsible for frequent hospital admissions. In this study we aimed to compare the effects of two enhancing strategies, the nebulized ketamine and IV magnesium sulfate, in treatment of severe steroid resistant asthma. MATERIALS AND METHODS: This double-blind randomized clinical trial was conducted on patients who presented to a referral clinic in Alborz, Iran. Using random allocation, patients were divided into two groups. The first group was treated with nebulized ketamine and the second group was treated with intravenous magnesium sulfate. Peak expiratory flow rates were assessed before the intervention, 30 and 60 min after the intervention and compared with the aid of SPSS software. RESULTS: The Peak expiratory flow rates before the intervention, 30 min and 60 min after the intervention was statistically significantly different in both ketamine and magnesium sulfate groups. Peak expiratory flow rates change between 0 and 60 min were 29.4 and 15.2% in the ketamine and magnesium sulfate group respectively. Although the ketamine group showed much higher increase in mean PEFR compared to the MgSO(4) groups, there was no statistically significant difference across both groups. CONCLUSION: Our study concluded that combined with standard therapy, both ketamine and IV magnesium sulfate are effective agents in the improvement of PEFR in patients with acute severe asthma that failed to respond to traditional therapies. However, there were no statistically significant difference between the two groups. BioMed Central 2021-11-30 /pmc/articles/PMC8630847/ /pubmed/34847965 http://dx.doi.org/10.1186/s40733-021-00081-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Farshadfar, Kimia
Sohooli, Maryam
Shekouhi, Ramin
Taherinya, Ali
Qorbani, Mostafa
Rezaei-kojani, Mehdi
The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial
title The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial
title_full The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial
title_fullStr The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial
title_full_unstemmed The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial
title_short The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial
title_sort effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630847/
https://www.ncbi.nlm.nih.gov/pubmed/34847965
http://dx.doi.org/10.1186/s40733-021-00081-1
work_keys_str_mv AT farshadfarkimia theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT sohoolimaryam theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT shekouhiramin theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT taherinyaali theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT qorbanimostafa theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT rezaeikojanimehdi theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT farshadfarkimia effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT sohoolimaryam effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT shekouhiramin effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT taherinyaali effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT qorbanimostafa effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial
AT rezaeikojanimehdi effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial